2019
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
Buckley L, Suarez‐Almazor M. Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer? Arthritis & Rheumatology 2019, 71: 1971-1973. PMID: 31379056, DOI: 10.1002/art.41064.Peer-Reviewed Original Research
2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment